Kornimate/medical-research-clean huggingface dataset:
the effect of guided imagery on the third stage of labor

Conditions: Third Stage of Labor; Bleeding; Guided Imagery; Childbirth

Summary: the purpose of this study was to evaluate the effect of guided imagery on the third stage of labor. blood loss from hemorrhage during childbirth, most commonly due to uterine atony, is one of the leading causes of maternal mortality in the united states and the leading cause of maternal death worldwide. the hypothesis was that the use of physiologic guided imagery would reduce the amount of bleeding during the third stage of labor.


Eligibility criteria:
inclusion criteria: * 18 years of age or older but less than 35 years * english as her primary language * fetus in a cephalic presentation * singleton pregnancy * 36 to 38 estimated gestational weeks * no contraindications to vaginal delivery * maternal weight less than 200 pounds prior to pregnancy exclusion criteria: * more than four previous children * a history of postpartum hemorrhage * bleeding disorder * seizure disorder * polyhydramnios * diabetes (including gestational) * hypertension * cardiac disease * uterine fibroids * anemia (hematocrit less than 30) * intrauterine fetal demise or tobacco use

Keywords: third stage of labor bleeding guided imagery childbirth
analysis of the dynamics of the lung microbiota during acute exacerbation of copd requiring admission to intensive care unit

Conditions: Chronic Obstructive Pulmonary Disease

Summary: this study aims to investigate the correlation between pulmonary microbiota dynamics (including bacteria, fungi and viruses) and copd exacerbation for copd patients admitted to icu

chronic obstructive pulmonary disease (copd) is a frequent cause of icu admission. copd exacerbations are a leading cause of lung function worsening and of morbimortality. hospitalizations due to copd exacerbations are highly expensive for health insurance system. bacterial pulmonary microbiota has been shown to be correlated to the severity of copd and to exacerbations. nevertheless fungi and viruses which are full actors of pulmonary microbiota have not yet been investigated. our primary outcome will be the assessment of alpha and beta diversity dynamics of the whole pulmonary microbiota (bacteria, fungi and viruses) between copd exacerbation and steady state. this study will prospectively include 24 patients at icu admission for copd exacerbation with sputum sampling. steady-state as defined during a 2 months-later visit will be studied with another sputum collection.

Eligibility criteria:
inclusion criteria: * patient above 18 admitted in icu * admitted for copd exacerbation defined by sustained (\> 2 days) worsening of respiratory symptoms considering anthonisen's criteria with life-threatening condition. * needing mechanical ventilation (noninvasive ventilation or oro-tracheal intubation) * copd condition will be presumed according to patient's respiratory history or previous lung function testing * able to consent or with the patient's family consent * affiliated to a social insurance scheme no inclusion criteria: * copd patient admitted for another cause than respiratory failure * person under tutorship or curatorship * living further than 100 kilometers away from the icu * expected survival inferior to 1 week exclusion criteria - lung function testing not consistent with copd at steady-state visit

Keywords: pulmonary microbiota chronic obstructive pulmonary disease
an observational study of cisatracurium 0.15 mg/kg in young and elderly (≥ 80 years) patients.

Conditions: Onset Time of Cisatracurium; Duration of Action of Cisatracurium; Intubation Conditions

Summary: the aim of this study is to determine the onset time, duration of action and effect on intubation conditions of cisatracurium 0.15 mg/kg in elderly patients with age ≥ 80 years and in young patients aged 18 - 40 years.

the aim of this study is to determine the onset time, duration of action and effect on intubation conditions of cisatracurium 0.15 mg/kg in elderly patients with age ≥ 80 years and in young patients aged 18 - 40 years. the hypothesis of this study is that cisatracurium administered in elderly patients (\>80 years) has a longer onset time and duration of action compared to younger patients.

Eligibility criteria:
inclusion criteria: 1. patients ≥ 80 or ≥18 - ≤40 years of age 2. informed consent 3. scheduled for elective surgery under general anaesthesia (expected duration of anaesthesia \> 1 hour) with intubation and use of cisatracurium 4. american society of anaesthesiologists (asa) physical status classification i to iii 5. can read and understand danish exclusion criteria: 1. known allergy to cisatracurium 2. neuromuscular disease 3. indication for rapid sequence induction 4. surgery in the prone position
can we antagonize mivacurium with neostigmine ?

Conditions: Mivacurium; Neostigmine; Residual Paralysis

Summary: the antagonism of neuromuscular blocking agents (nmba) (or curares), as well as the antagonism of other drugs used in anesthesia, is a major challenge for the speciality. residual paralysis is indeed a risk factor for post-operative morbidity and mortality and antagonization of curares at the end of the procedure is associated with a reduction in mortality . its use should be as large as possible and its contraindications are extremely rare. the antagonism of the nmba reduces the duration of the neuromuscular block and the complications that are associated . in this study, the investigators use mivacurium (or mivacron) as non-depolarizing curare and neostigmine as an antagonist. neostigmine reduces the duration of the neuromuscular block induced by mivacurium, by reducing the breakdown of acetylcholine, neostigmine induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade. but the use of neostigmine in current practice is not very widespread in this clinical situation. the reduction in the duration of the block is significant in comparison with a spontaneous recovery . moreover, spontaneous recovery is not always complete and sometimes very long. nevertheless, its action is effective and this study could support this use but also specify the duration and the quality of the return to normal of the neuromuscular transmission.


Eligibility criteria:
inclusion criteria: * patients american society of anesthesiologists (asa) 1 to 3 * absence of neuromuscular disease, renal and hepatic insufficiency * absence of medication that could interfere with the mediators of the neuromuscular junction exclusion criteria: * bronchial asthma * parkinson disease * bmi\> 35 * known hypersensitivity to neostigmine or to any of the excipients of neostigmine

Keywords: mivacurium neostigmine antagonism
loxl1 polymorphism in pseudoexfoliation syndrome

Conditions: Pseudoexfoliation Syndrome

Summary: to evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the korean population, genotypes of lysyl oxidase-like 1 gene were analyzed by direct sequencing.

to evaluate the association profiles of the lysyl oxidase-like 1 gene polymorphisms with pseudoexfoliation syndrome in the korean population, peripheral blood sampling will be done from the patients with pseudoexfoliation. and genotypes of the three single nucleotide polymorphisms of lysyl oxidase-like 1 gene , rs1048661, rs3825942, rs2165241 were analyzed by direct sequencing.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of pseudoexfoliation exclusion criteria: * medical condition that peripheral blood sampling cannot be done
neurocognitive follow-up (fu) study

Conditions: Cognitive Developmental Delay

Summary: this is a follow-up study of a recently completed trial (17.14.inf) evaluating the growth of pre-term infants. enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (ca).

this is a follow-up study of a recently completed multi-center, prospective, single-arm, open-label interventional trial (17.14.inf - alprem rtf: nct03728764) evaluating the growth of pre-term infants receiving a two-stage ptf feeding system while in the neonatal care unit and continuing until 30 days post-discharge. enrolled children will undergo neurocognitive assessments at 18- and 24-months of corrected age (ca). the timing of the cognitive assessments aligns with routine check-up visits and reflect the period at which developmental delays may first become evident.

Eligibility criteria:
inclusion criteria: 1. infants / children born prematurely who were enrolled into the original clinical trial and who are less than 24 m of ca. 2. having obtained his / her parents' (or his or her legally accepted guardian written informed consent and having evidence of personally signed and dated informed consent document indicating that the child's parent(s) / legal guardian has been informed of all pertinent aspects of the study. exclusion criteria: 1. infants identified retrospectively as not meeting the inclusion or exclusion criteria for the original study.
a study of gemcitabine/nab-paclitaxel and radiation therapy followed by surgery in patients with advanced pancreatic cancer

Conditions: Pancreatic Cancer

Summary: this is a phase 1 (the first phase in testing a new drug, to see how safe a new drug or new indication/population ) and phase 2 (the second phase in testing a new drug or new indication/population to see how effective the drug is) study of neoadjuvant (treatment before the main treatment) with gemcitabine and nab-paclitaxel (abraxane) and gemcitabine and radiation therapy before surgery and then gemcitabine and nab-paclitaxel after surgery in patients with pancreatic cancer that has grown to involve one of the major artery branches.

gemcitabine and nab-paclitaxel are chemotherapy drugs that are currently approved by health canada for use in combination for the treatment of pancreatic cancer. however, the combination of gemcitabine and nab-paclitaxel as a neoadjuvant treatment prior to gemcitabine and radiation is experimental. surgery to remove or reconstruct the major artery is also experimental.

Eligibility criteria:
inclusion criteria: surgical: * medically fit for major pancreatic surgery * no evidence of metastases * no prior resection * arterial involvement limited to a single major vessel and is resectable * tumour-free margins could be achieved * acceptable length of vessel * mass considered otherwise resectable by current standards general: * less than 70 years old * performance status \<=2 * has pancreatic adenocarcinoma * adequate bone marrow and organ function * therapeutic heparin is allowed * taking chronic erythropoietin are permitted * not pregnant * agree to use contraception * able to provide written consent exclusion criteria: surgical: * aortic involvement * involvement of 2 major arterial trunks * smv/portal venous occlusion, cannot be reconstructed * extensive venous involvement, no arterial involvement * disease progression on neo-adjuvant treatme general: * concurrent cancer diagnosis * other malignancies unless all therapy completed, no disease for \>=3 years * prior radiotherapy or chemo within 1 year, to pancreas * bone marrow transplant/stem cell rescue * major surgery \<4 wks prior * distant metastases * renal dysfunction * pulmonary insufficiency * history of cardiac disease * active systemic infection(s) or any other related illnesses * known hiv, hbv, hcv * history of solid organ transplant, cardiovascular disease, inflammatory bowel disease, or underlying neuropathy * conditions interfering with patient participation * known or suspected allergy to study drugs * pregnant or breast-feeding * therapeutic coumadin * more than or equal to grade 2 pre-exiting peripheral neuropathy

Keywords: blood vessels reconstructive surgery
mri-based synthetic ct images of the head and neck

Conditions: Imaging of Bony Structures of the Head (Various Conditions); Hearing Loss; Cholesteatoma; Sinusitis; Head and Neck Tumor

Summary: in case of surgical procedures in the head and neck region, mri in combination with ct of the bone is often the standard modality to visualise bony landmarks for planning, navigation and risk assessment. an important downside of a ct scan is the associated radiation exposure, especially in children. an additional downside is the sedation or general anaesthesia needed for both the mri and ct scan session in very young children. these downsides could be removed if the ct scan can be substituted by an mri sequence that can provide the same information as ct. this project aims to determine the feasibility of recreating ct like images of the craniofacial bones from mri images using machine learning techniques.


Eligibility criteria:
inclusion criteria: * patients from the outpatient ent (ear, nose, throat)-clinic. * aged 18 years or older. * referred for ct scan of the mastoid, sinonasal complex or face. exclusion criteria: * pregnancy. * contra-indications for mri or ct. * unwillingness to be informed about possibly clinically relevant, incidental findings from the mri examination.

Keywords: mri synthetic ct artificial intelligence craniofacial
infliximab ibd influenza vaccine study

Conditions: Inflammatory Bowel Disease

Summary: the investigators will compare the immunogenicity of influenza vaccine in adults and children with inflammatory bowel disease by timing of vaccine in relation to maintenance infliximab dosing. the primary objective is to compare the proportion of ibd patients on maintenance infliximab who mount serologic protection to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion (day 0 to 4) and patients vaccinated at the mid-point between infliximab infusions (day 21 to 28). serologic protection will be defined by a hemagglutination-inhibition titer ≥ 1:40. the secondary objective is to compare the proportion of ibd patients who mount an immunogenic response (≥ 4-fold increase from pre to post-vaccination titer) to each component of the influenza vaccination between patients vaccinated on day of infliximab infusion and those vaccinated at the mid-point.


Eligibility criteria:
inclusion criteria: * diagnosis of ibd established by accepted criteria * on maintenance infliximab administered every 6 to 8 weeks (already received at least 6 weeks of infliximab) * between ages 9 and 60 years exclusion criteria: 1. pregnancy 2. hypersensitivity reaction to previous dose of influenza vaccine 3. known hypersensitivity to eggs or chicken or other components of influenza vaccine

Keywords: influenza vaccine immune response remicade (infliximab) inflammatory bowel disease
efficacy of topical cyclosporin for ocular rosacea

Conditions: Rosacea

Summary: the purpose of this study is to determine whether restasis (topical cyclosporin) is effective in the treatment of ocular rosacea

the study is designed to compare the efficacy of topical cyclosporin (restasis) with that of refresh endura for the treatment of the signs and symptoms of ocular rosacea in patients presently controlled on topical corticosteroids

Eligibility criteria:
inclusion criteria: * patient at least 18 years old, but younger than 65 * diagnosis of acne rosacea * active ocular rosacea based on lid findings of meibomian gland dysfunction with lid telangiectasia and hyperemia of at least 2+ * schirmers test of greater than 5mm in at least 1 eye * if patient currently using lid hygiene must maintain regimen during study * stop oral antibiotics at least 4 weeks prior exclusion criteria: * use of topical cyclosporin within last 90 days * visual acuity of 20/100 or better in both eyes * pregnant or lactating females * active ocular infection * scarring of central cornea * eyelid defects,abnormal lid positioning or lagophthalmos * flax seed or fish oil supplements within last 30 days
dairy macronutrient effects on the metabolic syndrome

Conditions: Metabolic Syndrome

Summary: the investigators examined the effects of 4-week dietary protein intake in mixed meals at two levels of protein amount on whole body glucose metabolisms in older adults with metabolic syndrome.

the investigators investigated changes in insulin sensitivity before and after 4 weeks of dietary intervention and control in subjects with metabolic syndrome. two groups of subjects were studied before and after a weight maintenance diet. group 1 was fed a common american diet with a macronutrient distribution of 10% protein, 55% carbohydrates, and 35% fat. group 2 consumed a higher protein diet (20%; 1.4 g/kg/d of protein). carbohydrate intake was lower in group 2 (45%), with fat intake (largely derived from dairy sources) similar between groups. glucose utilization and endogenous glucose production were determined during an oral glucose tolerance test (ogtt) with a novel double-tracer approach. the secondary aim was to determine the effect of a diet high in dairy consumption on blood lipid profiles. the investigators measured blood lipids before and after dietary intervention in each group.

Eligibility criteria:
inclusion criteria: * men and women, ages 45-75 years and * bmi greater than 30 kg/m2 and * two of the following conditions: * plasma triglycerides \> 130 mg/dl * hdl \< 40 mg/dl in men or 50 mg/dl in women * elevated screening blood pressure (systolic \> 140 or diastolic \>90 mm hg) or taking medication for hypertension * fasting plasma glucose \> 100mg/dl exclusion criteria: * hemoglobin a1c \> 7.5 * history of malignancy in the 6 months prior to enrollment * history of lactose intolerance or dairy allergy * history of gastrointestinal bypass surgery (lapband, etc) * history of a chronic inflammatory condition or disease (lupus, hiv/aids, etc) * subjects who do not or will not eat animal proteins * subjects who cannot refrain from consuming protein or amino acid supplements during their participation in this study * subjects who use insulin to control their blood sugar * subjects whose physician will not allow suspension of oral diabetes medications for the duration of the study (\~5 weeks) * concomitant use of corticosteroids (ingestion, injection or transdermal) * any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician
effect of aerobic exercise training in obese adults

Conditions: Obesity

Summary: to determine the effect of aerobic exercise training on arterial stiffness and hemodynamics in obese adults. proper evidence on the effect of aerobic exercise training on both arterial stiffness and hemodynamics are sparsely present in obese adults whereas separate studies were done in mainly hypertensive and cardiovascular disease populations.

obese adults always have been trying to improve their quality of life by managing the complications associated with obesity like arterial stiffness and disturbed hemodynamics.

Eligibility criteria:
inclusion criteria: * body mass index ≥28 kg/m² * able to do exercise exclusion criteria: * involved in structured physical activity in last 6 months * history of chronic systemic disease (cardiovascular, pulmonary, and metabolic disease) * continuous medication use. * msk or neurological problems * pregnant females

Keywords: aerobic exercise, arterial stiffness, hemodynamics, obesity
in vivo pulse oximeter validation study

Conditions: Hypoxia

Summary: the goal of this clinical trial is to compare values of spo2 provided by the dut and the sao2 used as a reference in healthy adults. the main question it aims to answer is: what is the accuracy of the subject device compared to the 510(k)-cleared reference device a radial arterial cannula was placed in the wrist of each subject for arterial blood sampling and a subject device was placed on each arm of the patients. then, hypoxia was induced to different stable levels of oxyhemoglobin saturation between 70-100% by having subjects breathe mixtures of nitrogen, air, and carbon dioxide controlled by the study physician. values of spo2 and sao2 were then compared to provide a root mean square error and conclude on the subject device accuracy.


Eligibility criteria:
inclusion criteria: * healthy adult * normal hemoglobin levels (hemoglobin \> 10 g/dl) exclusion criteria: * systemic illness * obesity
cancer genome study using samples from patients with stage i or stage ii non-small cell lung cancer treated on clinical trial acosog-z0030

Conditions: Lung Cancer

Summary: rationale: studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research study is looking at the cancer genome using tumor samples from patients with stage i or stage ii non-small cell lung cancer treated on clinical trial acosog-z0030.

objectives: * to investigate the clinical relevance of conducting comprehensive molecular analyses on clinically annotated high-quality tumor biospecimens from patients with stage i or ii, n0 or n1 (less than hilar) non-small cell lung cancer. outline: this is a multicenter study. biological specimens are collected from participating clinical sites and analyzed by transcription profiling of rna and microrna; detection of dna copy number changes and chromosomal rearrangements; epigenetic modifications analyses; and sequencing of genomic segments, genes, and regulatory regions to assess sequence variation. clinical information associated with each specimen donor is also collected.

Eligibility criteria:
disease characteristics: * diagnosis of non-small cell carcinoma * primary, untreated disease * stage i or ii (t1 or t2, n0 or non-hilar n1, m0) disease * any of the following histologies allowed: * squamous cell carcinoma * adenocarcinoma (\< 10%) * large cell carcinoma (high-grade) * available tumor tissue samples collected on clinical trial acosog-z0030 and meeting the following criteria: * snap-frozen and stored at a temperature of -80°c or lower * specimens may come from any site within the lung or one that is involved by direct regional extension of tumor from the originating site in the lung * no regional lymph node or distant metastases * no recurrent or persistent disease after prior neoadjuvant or adjuvant treatment for lung cancer * must have matching frozen samples of normal tissue and blood

Keywords: adenocarcinoma of the lung large cell lung cancer squamous cell lung cancer stage i non-small cell lung cancer stage ii non-small cell lung cancer